CL2007002562A1 - Conjunto para entrega de drogas, espacial y temporalmente programable de ingrediente activo que comprende un nucleo, una o mas capas de recubrimiento y un espacio hueco preformado, en que el ingrediente activo esta presente en el nucleo o en cualquie - Google Patents

Conjunto para entrega de drogas, espacial y temporalmente programable de ingrediente activo que comprende un nucleo, una o mas capas de recubrimiento y un espacio hueco preformado, en que el ingrediente activo esta presente en el nucleo o en cualquie

Info

Publication number
CL2007002562A1
CL2007002562A1 CL200702562A CL2007002562A CL2007002562A1 CL 2007002562 A1 CL2007002562 A1 CL 2007002562A1 CL 200702562 A CL200702562 A CL 200702562A CL 2007002562 A CL2007002562 A CL 2007002562A CL 2007002562 A1 CL2007002562 A1 CL 2007002562A1
Authority
CL
Chile
Prior art keywords
nucleus
active ingredient
space
drug delivery
present
Prior art date
Application number
CL200702562A
Other languages
English (en)
Spanish (es)
Inventor
Singh Sarabjit Singh S Amarjit
Original Assignee
M S Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M S Panacea Biotec Ltd filed Critical M S Panacea Biotec Ltd
Publication of CL2007002562A1 publication Critical patent/CL2007002562A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200702562A 2006-09-04 2007-09-04 Conjunto para entrega de drogas, espacial y temporalmente programable de ingrediente activo que comprende un nucleo, una o mas capas de recubrimiento y un espacio hueco preformado, en que el ingrediente activo esta presente en el nucleo o en cualquie CL2007002562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1411MU2006 2006-09-04

Publications (1)

Publication Number Publication Date
CL2007002562A1 true CL2007002562A1 (es) 2008-02-08

Family

ID=39430167

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702562A CL2007002562A1 (es) 2006-09-04 2007-09-04 Conjunto para entrega de drogas, espacial y temporalmente programable de ingrediente activo que comprende un nucleo, una o mas capas de recubrimiento y un espacio hueco preformado, en que el ingrediente activo esta presente en el nucleo o en cualquie

Country Status (16)

Country Link
US (1) US8277843B2 (enExample)
EP (1) EP2068844A4 (enExample)
JP (1) JP2010502591A (enExample)
KR (1) KR20090065524A (enExample)
CN (1) CN101511346B (enExample)
AR (1) AR062644A1 (enExample)
AU (1) AU2007323018B2 (enExample)
BR (1) BRPI0716481A2 (enExample)
CA (1) CA2661172A1 (enExample)
CL (1) CL2007002562A1 (enExample)
IL (1) IL197121A0 (enExample)
MX (1) MX2009002371A (enExample)
NO (1) NO20090807A (enExample)
RU (1) RU2420268C2 (enExample)
WO (1) WO2008062440A2 (enExample)
ZA (1) ZA200901162B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
WO2009153635A1 (en) * 2008-06-19 2009-12-23 University Of Witwatersrand, Johannesburg A chronotherapeutic pharmaceutical dosage form
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
EP2457561A4 (en) * 2009-07-06 2014-03-05 Kyorin Seiyaku Kk TABLET WITH HIGH STRUCTURE
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
US20110177231A1 (en) * 2010-01-16 2011-07-21 Alexander Grinberg Nano-, Micro-, Macro- Encapsulation And Release Of Materials
JP2013519726A (ja) * 2010-02-17 2013-05-30 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド バクロフェン療法に感受性の病状の治療方法
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
GB201102148D0 (en) * 2011-02-08 2011-03-23 Ucl Business Plc Layered bodies, compositions containing them and processes for producing them
EP2731609A1 (en) * 2011-07-14 2014-05-21 APeT Holding B.V. Nicotinamide compositions and the therapeutic use thereof
EP3446685A1 (en) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
JP2016533864A (ja) * 2013-10-22 2016-11-04 キャプソ・ヴィジョン・インコーポレーテッド マルチ密度相を有するカプセル装置に用いられるシステム及び方法
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CN116370644A (zh) 2014-06-11 2023-07-04 麻省理工学院 驻留结构及相关方法
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
CN119925721A (zh) 2016-05-27 2025-05-06 林德拉治疗公司 用于胃驻留系统的材料结构
CN118766834A (zh) 2016-09-30 2024-10-15 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
JP6957610B2 (ja) * 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
WO2019025869A1 (en) * 2017-07-31 2019-02-07 Teva Pharmaceutical Industries Limited GALENIC FORMS WITH CONTROLLED RELEASE MANUFACTURED IN ADDITIVE MANNER
US11337919B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
IL275312B2 (en) 2017-12-18 2024-09-01 Tris Pharma Inc Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
CA3148226A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
TWI763036B (zh) * 2020-09-14 2022-05-01 王子賓 可膨脹微膠囊
WO2022195586A1 (en) 2021-03-15 2022-09-22 Epitomee Medical Ltd. Expandable devices for delivery of active agents to tissues
WO2024062466A1 (en) 2022-09-21 2024-03-28 Epitomee Medical Ltd. Controllably disintegrable self-expandable ingestible devices
NL2033549B1 (en) * 2022-11-17 2024-05-28 Taiwan Mercury Medical Corp Metformin tablet for relieving pain and reducing inflammation and manufacturing method thereof
AU2024265092A1 (en) * 2023-05-03 2025-11-20 Dark Canyon Laboratories, Llc A floating drug delivery system for solid forms of salts used in bowel cleansing products

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512411B2 (enExample) * 1974-03-12 1980-04-02
JPS5134879A (en) * 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
JPH03101615A (ja) * 1989-09-14 1991-04-26 Sumitomo Pharmaceut Co Ltd 胃内滞留型持続性製剤
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
ID21477A (id) * 1997-03-26 1999-06-17 Janssen Pharmaceutica Nv Pelet-pelet yang mempunyai inti yang dilapisi dengan suatu anti jamur dan suatu polimer
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6050796A (en) 1998-05-18 2000-04-18 General Motors Corporation Vane pump
WO2001058424A1 (en) 2000-02-09 2001-08-16 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Floating drug delivery composition
JP2002370970A (ja) * 2001-06-12 2002-12-24 Sanwa Kagaku Kenkyusho Co Ltd 胃内浮遊型固形製剤及びその製造方法
IL159715A0 (en) * 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
EP1574534A1 (en) * 2004-03-11 2005-09-14 Rohm And Haas Company Polymer carriers and process

Also Published As

Publication number Publication date
WO2008062440A3 (en) 2008-07-31
ZA200901162B (en) 2010-06-30
KR20090065524A (ko) 2009-06-22
EP2068844A4 (en) 2013-01-23
AU2007323018B2 (en) 2011-02-03
AU2007323018A1 (en) 2008-05-29
NO20090807A (no) 2009-06-04
US8277843B2 (en) 2012-10-02
AR062644A1 (es) 2008-11-19
CN101511346A (zh) 2009-08-19
CA2661172A1 (en) 2008-05-29
MX2009002371A (es) 2009-03-12
RU2420268C2 (ru) 2011-06-10
BRPI0716481A2 (pt) 2014-03-18
IL197121A0 (en) 2009-11-18
CN101511346B (zh) 2012-07-04
EP2068844A2 (en) 2009-06-17
RU2009112396A (ru) 2010-10-20
WO2008062440A2 (en) 2008-05-29
US20100015224A1 (en) 2010-01-21
JP2010502591A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
CL2007002562A1 (es) Conjunto para entrega de drogas, espacial y temporalmente programable de ingrediente activo que comprende un nucleo, una o mas capas de recubrimiento y un espacio hueco preformado, en que el ingrediente activo esta presente en el nucleo o en cualquie
CY2025003I1 (el) Λιποσωματα για τη χορηγηση φαρμακων
DK2692341T3 (da) Misbrugs-resistent lægemiddelformulering
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
IL190499A0 (en) Sustained release small molecule drug formulation
BRPI0810899A2 (pt) Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais.
DK2612645T3 (da) Lægemiddellagrings- og dispenseringsindretninger og systemer omfattende samme
IL250674B (en) A compound for administering a drug through the large intestine
EP2081550A4 (en) COATING OF CAPSULES WITH PHARMACEUTICAL ACTIVE SUBSTANCES
ATE479449T1 (de) Lufterfrischer vom spraytyp mit bewegungsmelder
PL1749759T3 (pl) Końcówka dozująca do rozpylacza
IL193274A0 (en) Pharmaceutical formulation for aerosols, comprising two or more active agents and at least one surfactant
IL231322A0 (en) Intraocular drug delivery systems
ZA200808401B (en) Drug delivery methods, structures, and compositions for nasolacrimal system
DK2370045T3 (da) Patron, lægemiddeldispenser til lægemiddelportioner i fast form samt anvendelse af patronen og lægemiddeldispenseren
ZA200806496B (en) Drug delivery systems comprising weakly basic drugs and organic acids
BRPI0716090A2 (pt) dispensador, e, embalagem de recarga dispensadora
ZA200710865B (en) New regimens for controlled drug delivery devices for contraception
IL198636A0 (en) Pesticide composition comprising fosetyl-aluminium and an insecticide active substance
IL198635A0 (en) Pesticide composition comprising fosetyl-aluminium, propamocarb- hcl and an insecticide active substance
DK2001297T3 (da) Aktivstofkombinationer insekticide egenskaber
EP1922025A4 (en) MEDICAMENT-FREE IMPLANT
IL216104A0 (en) Coated drug delivery formulations
DK2077739T3 (da) Hyldeafsnit, som er drejeligt mellem en fremvisnings- og en genopfyldningsposition
ATE408664T1 (de) Abgabesystem für wirkstoff